INVESTIGACIÓN CLÍNICA
Grupo de Neoplasias Ginecológicas

ANA OAKNIN

ANA OAKNIN
Principal Investigator
Biosketch

OBJETIVOS ESTRATÉGICOS

  • Determinar los mejores métodos de tratamiento en tumores ginecológicos malignos en estudios avanzados a través de ensayos clínicos internacionales.
  • Contribuir al desarrollo clínico precoz de fármacos contra cánceres ginecológicos.
  • Consolidar un programa de investigación traslacional para avanzar en la medicina de precisión.

OBJETIVOS ACTUALES

  • Investigación clínica en neoplasias malignas ginecológicas y en desarrollo de terapias innovadoras para el tratamiento de tumores ginecológicos. A modo de ejemplo, nuestro trabajo de investigación clínica ha conducido a la autorización de un nuevo tratamiento de referencia para el cáncer de ovario recidivante y resistente (ensayo AURELIA) y para el cáncer de cuello uterino metastásico (ensayo GOG240).
  • Ampliar la colaboración con otros grupos de investigación internacionales de referencia: el Gynecologic Cancer Inter Group (GCIG) (como representante español del Cervical Cancer Committee), el Gynecologic Oncology Group (GOG), la European Network of Gynaecological Oncology Trial Groups (ENGOT), y el Grupo Español de Investigación en Cáncer de Ovario (GEICO).
  • Continuar siendo un centro de referencia para la mayoría de los hospitales regionales y centros a nivel nacional.
  • Centrar la investigación en los nuevos inhibidores de PARP tanto para pacientes con cáncer de ovario asociado a la mutación en el gen BRCA como para un grupo de pacientes bien definido con carcinoma ovárico de gran malignidad, y aumentar el conocimiento de la inmunoterapia y la angiogénesis.
  • Colaborar estrechamente con otros profesionales y especialistas (como cirujanos, radioterapeutas, radiólogos y anatomopatólogos del Hospital Universitario Valle de Hebrón) para establecer nuevos protocolos terapéuticos y pautas clínicas con el fin de mejorar la práctica clínica en oncología en el Hospital Universitario Valle de Hebrón (HUVH).

COMPONENTES

Gynecological Malignancies Group
  • Investigador Principal
    • Ana Oaknin
  • Médico Oncólogos y Becarios de Investigación
    • Lorena Fariñas
    • Victor Rodríguez-Freixinos
  • Especialista en Enfermería Clínica
    • Cristina Casal

Publicaciones científicas más relevantes

  • Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher; DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Marth C, Brize A, Fabbro M, Redondo A, Bamias: A, Ma H, Vogl FD, Bach BA, Oza AM. Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. Gynecol Oncol. 2016 Oct;143(1):27-34.
  • Fujiwara K, Monk BJ, Lhommé C, Coleman RL, Brize A, Oaknin A, Ray-Coquard I, Fabbro M, Provencher D, Bamias A, Vergote I, DeCensi A, Zhang K, Vogl FD, Bach BA, Raspagliesi F. Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1). Ann Oncol. 2016 Jun;27(6):1006-13.
  • Oaknin A, Rubio MJ, Redondo A, De Juan A, Cueva Bañuelos JF, Gil-Martín M, Ortega E, Garcia-Arias A, González-Martin A, Bover I.  SEOM guidelines for cervical cancer. Clin Transl Oncol 2015 Dec; 17(12): 1036-42
  • Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M.  Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015 Jan; 16(1): 87-97
  • Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ.  Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015 Aug; 16(8): 928-36
  • McMeekin S, Dizon D, Barter J, Scambia G, Manzyuk L, Lisyanskaya A, Oaknin A, Ringuette S, Mukhopadhyay P, Rosenberg J, Vergote I.  Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. Gynecol. Oncol. 2015 Jul; 138(1): 18-23
  • Floquet A, Vergote I, Colombo N, Fiane B, Monk BJ, Reinthaller A, Calvert P, Herzog TJ, Meier W, Kim JW, del Campo JM, Friedlander M, Pisano C, Isonishi S, Crescenzo RJ, Barrett C, Wang K, Mitrica I, du Bois A.  Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial. Gynecol. Oncol. 2015 Jan; 136(1): 37-42

Todas las publicaciones

  • Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher; DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Marth C, Brize A, Fabbro M, Redondo A, Bamias: A, Ma H, Vogl FD, Bach BA, Oza AM. Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. Gynecol Oncol. 2016 Oct;143(1):27-34.
  • Fujiwara K, Monk BJ, Lhommé C, Coleman RL, Brize A, Oaknin A, Ray-Coquard I, Fabbro M, Provencher D, Bamias A, Vergote I, DeCensi A, Zhang K, Vogl FD, Bach BA, Raspagliesi F. Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1). Ann Oncol. 2016 Jun;27(6):1006-13.
  • Liu JF, Ray-Coquard I, Selle F, Poveda AM, Cibula D, Hirte H, Hilpert F, Raspagliesi F, Gladieff L, Harter P, Siena S, Del Campo JM, Tabah-Fisch I, Pearlberg J, Moyo V, Riahi K, Nering R, Kubasek W, Adiwijaya B, Czibere A, Naumann RW, Coleman RL, Vergote I, MacBeath G, Pujade-Lauraine E. Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer. J Clin Oncol. 2016 Dec 20;34(36):4345-4353. Epub 2016 Oct 23.
  • Kurzeder C, Bover I, Marmé F, Rau J, Pautier P, Colombo N, Lorusso D, Ottevanger P, Bjurberg M, Marth C, Barretina-Ginesta P, Vergote I, Floquet A, Del Campo JM, Mahner S, Bastière-Truchot L, Martin N, Oestergaard MZ, Kiermaier A, Schade-Brittinger C, Polleis S, du Bois A, Gonzalez-Martin A. Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE). J Clin Oncol. 2016 Jul 20;34(21):2516-25.
  • González-Martín A, Pautier P, Mahner S, Rau J, Colombo N, Ottevanger P, Del Campo JM, Selle F, du Bois A, Gadducci A, García Y, Berton-Rigaud D, Marmé F, Ortega E, Martin N, Bastiere-Truchot L, Kiermaier A, Kurzeder C. Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial. Int J Gynecol Cancer. 2016 Jun;26(5):898-905.
  • Pujade-Lauraine E, Selle F, Weber B, Ray-Coquard IL, Vergote I, Sufliarsky J, Del Campo JM, Lortholary A, Lesoin A, Follana P, Freyer G, Pardo B, Vidal L, Tholander B, Gladieff L, Sassi M, Garin-Chesa P, Nazabadioko S, Marzin K, Pilz K, Joly F. Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l’Etude des Cancers de l’Ovaire Study. J Clin Oncol. 2016 Mar 1;34(7):706-13.
  • Harter P, Johnson T, Berton-Rigaud D, Park SY, Friedlander M, Del Campo JM, Shimada M, Forget F, Mirza MR, Colombo N, Zamagni C, Chan JK, Imhof M, Herzog TJ, O’Donnell D, Heitz F, King K, Stinnett S, Barrett C, Jobanputra M, Xu CF, du Bois A. BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study. Gynecol Oncol. 2016 Mar;140(3):443-9.
  • du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO, Merger M, Harter P; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2016 Jan;17(1):78-89.
  • Oaknin A, Rubio MJ, Redondo A, De Juan A, Cueva Bañuelos JF, Gil-Martín M, Ortega E, Garcia-Arias A, González-Martin A, Bover I.  SEOM guidelines for cervical cancer. Clin Transl Oncol 2015 Dec; 17(12): 1036-42
  • Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M.  Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015 Jan; 16(1): 87-97
  • Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ.  Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015 Aug; 16(8): 928-36
  • McMeekin S, Dizon D, Barter J, Scambia G, Manzyuk L, Lisyanskaya A, Oaknin A, Ringuette S, Mukhopadhyay P, Rosenberg J, Vergote I.  Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. Gynecol. Oncol. 2015 Jul; 138(1): 18-23
  • Floquet A, Vergote I, Colombo N, Fiane B, Monk BJ, Reinthaller A, Calvert P, Herzog TJ, Meier W, Kim JW, del Campo JM, Friedlander M, Pisano C, Isonishi S, Crescenzo RJ, Barrett C, Wang K, Mitrica I, du Bois A.  Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial. Gynecol. Oncol. 2015 Jan; 136(1): 37-42
  • Marth C, du Bois A, Schauer C, Casado A, Vergote I, del Campo JM, Goudopoulou A, Pujade-Lauraine E, Bruchim I, Colombo N, Pignata S, Ledermann J, Chekerov R, Raza Mirza M, Westermann A, Glasspool R, Taskiran C, Fehr M, Cibula D.  The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership. Int. J. Gynecol. Cancer 2015 Jul; 25(6): 1094-5
  • Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM.  Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014 Jul; 15(8): 799-808
  • Vergote I, Oaknin A, Baurain JF, Ananda S, Wong S, Su X, Wu B, Zhong Z, Warner D, Casado A.  A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery. Eur. J. Cancer 2014 Sep; 50(14): 2408-16
  • Abu-Rustum N, Chi D, Coleman RL, del Campo JM, Fotopoulou C, Frumovitz M, Gershenson DM, González A, Jhingran A, Ledermann J, Mariani A, Mirza M, Oaknin A, Ramirez PT, Schmeler KM, Sood AK.  Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: emerging therapies in gynecologic cancer. Gynecol. Oncol. 2014 Jul; 134(1): 6-9
  • Salazar R, Morales S, Gil-Martín M, Aguirre E, Oaknin A, García M, Callies S, Wickremsinhe ER, Benhadji KA, Llombart A.  Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2014 Jun; 73(6): 1205-15
  • Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I.  Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J. Clin. Oncol. 2014 May; 32(13): 1302-8
  • Llauradó M, Majem B, Altadill T, Lanau L, Castellví J, Sánchez-Iglesias JL, Cabrera S, de la Torre J, Díaz-Feijoo B, Perez-Benavente A, Colas E, Olivan M, Doll A, Alameda F, Matias-Guiu X, Moreno-Bueno G, Carey MS, del Campo JM, Gil-Moreno A, Reventos J, Rigau M.  MicroRNAs as prognostic markers in ovarian cancer. Mol. Cell. Endocrinol. 2014 Jun; 390(1): 73-84
  • Tewari KS, Sill MW, Long HJ, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ.  Improved survival with bevacizumab in advanced cervical cancer.N. Engl. J. Med. 2014 Feb; 370(8): 734-43
  • González-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G, Oaknin A, Sneller V, Freudensprung U, Pignata S.  Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer). Eur. J. Cancer 2014 Mar; 50(4): 862-3
  • Diaz-Padilla I, Monk BJ, Mackay HJ, Oaknin A.  Treatment of metastatic cervical cancer: future directions involving targeted agents. Crit. Rev. Oncol. Hematol. 2013 Mar; 85(3): 303-14
  • Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, Baumann KH, Kurzeder C, Schmalfeldt B, Cibula D, Bidzinski M, Casado A, Martoni A, Colombo N, Holloway RW, Selvaggi L, Li A, del Campo J, Cwiertka K, Pinter T, Vermorken JB, Pujade-Lauraine E, Scartoni S, Bertolotti M, Simonelli C, Capriati A, Maggi CA, Berek JS, Pfisterer J.  Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO–the MIMOSA study. J. Clin. Oncol. 2013 Apr; 31(12): 1554-61
  • del Campo JM, Sessa C, Krasner CN, Vermorken JB, Colombo N, Kaye S, Gore M, Zintl P, Gómez J, Parekh T, Park YC, McMeekin S.  Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials. Med. Oncol. 2013 Mar; 30(1): 435
  • González-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G, Kovalenko N, Oaknin A, Ronco JP, Freudensprung U, Pignata S.  Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer. Eur. J. Cancer 2013 Dec; 49(18): 3831-8
  • Vergote I, Elser G, Votan B, Farrelly L, De Roover J, Bryce J, du Bois A.  Roadmap for the European Network of Gynaecological Trial groups (ENGOT) Trials. Int. J. Gynecol. Cancer 2013 Sep; 23(7): 1339-43
  • Sehouli J, del Campo JM, Lorusso D.  Discussion: session 1. Future Oncol 2013 Dec; 9(12): 25-7
  • del Campo JM, Sehouli J, Lorusso D.  Discussion: session 2. Future Oncol 2013 Dec; 9(12): 37-9
  • González Martín A, Redondo A, Jurado M., De Juan A, Romero I., Bover I, del Campo JM, Cervantes A, García Y, Lopez-Guerrero JA, Mendiola C, Palacios J, Rubio MJ, Poveda A.  GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012. Clin Transl Oncol. 2013 Mar;
  • Cedrés S, Montero MA, Martínez P, Martínez A, Rodríguez-Freixinos V, Torrejón D, Gabaldon A, Salcedo M, Ramón y Cajal S, Felip E.  Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). Lung Cancer 2012 Jul; 77(1): 192-8
  • Oaknin A, Diaz de Corcuera I, Rodríguez-Freixinos V, Rivera F, del Campo JM.  SEOM guidelines for cervical cancer. Clin Transl Oncol 2012 Jul; 14(7): 516-9
  • Oaknin A, Rodríguez-Freixinos V, Diaz de Corcuera I, Rivera F, del Campo JM.  SEOM guidelines for endometrial cancer. Clin Transl Oncol 2012 Jul; 14(7): 512-5
  • Salazar R, Jones RJ, Oaknin A, Crawford D, Cuadra C, Hopkins C, Gil M, Coronado C, Soto-Matos A, Cullell-Young M, Iglesias Dios JL, Evans TR.  A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2012 Nov; 70(5): 673-81
  • Diaz-Padilla I, Razak AR, Minig L, Bernardini MQ, María Del Campo J.  Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls. Clin Transl Oncol 2012 Jan; 14(1): 15-20
  • Oaknin A, Roda D, González-Martin A, Chiva L, García-Donas J, De Juan A, Redondo A, Martínez S, García Y, Catot S, Ponce J, del Campo JM, Cervantes A, Poveda A.  Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study. Int. J. Gynecol. Cancer 2011 Aug; 21(6): 1048-55
  • Whitcher B, Schmid VJ, Collins DJ, Orton MR, Koh DM, Diaz de Corcuera I, Parera M, del Campo JM, DeSouza NM, Leach MO, Harrington K, El-Hariry IA.  A Bayesian hierarchical model for DCE-MRI to evaluate treatment response in a phase II study in advanced squamous cell carcinoma of the head and neck. MAGMA 2011 Apr; 24(2): 85-96
  • del Campo JM, Hitt R, Sebastian P, Carracedo C, Lokanatha D, Bourhis J, Temam S, Cupissol D, De Raucourt D, Maroudias N, Nutting CM, Compton N, Midwinter D, Downie L, Biswas-Baldwin N, El-Hariry I, Harrington KJ.  Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. Br. J. Cancer 2011 Aug; 105(5): 618-27
  • Cedrés S, Prat A, Martínez P, Pallisa E, Sala G, Andreu J, del Campo JM, Quispe I, Baselga J, Felip E. Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib. Lung Cancer 2009 Nov; 66(2): 257-61
  • Prat A, Parera M, Adamo B, Peralta S, Perez-Benavente MA, Garcia A, Gil-Moreno A, Martinez-Palones JM, Baselga J, del Campo JM.  Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels. Ann. Oncol. 2009 Feb; 20(2): 294-7
  • del Campo JM, Roszak A, Bidzinski M, Ciuleanu TE, Hogberg T, Wojtukiewicz MZ, Poveda A, Boman K, Westermann AM, Lebedinsky C.  Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann. Oncol. 2009 Nov; 20(11): 1794-802
  • Vergote I, Finkler N, del Campo J, Lohr A, Hunter J, Matei D, Kavanagh J, Vermorken JB, Meng L, Jones M, Brown G, Kaye S.  Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur. J. Cancer 2009 Sep; 45(13): 2324-32